Results 41 to 50 of about 3,108,169 (356)

Emerging targeted therapies for melanoma treatment (Review) [PDF]

, 2014
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development of novel therapies for this ...
Agarwala, Akinleye, ANGELA RUSSO, ANTONIO BIONDI, Antony, Aplin, Ascierto, Ascierto, Ascierto, Awada, BARTOLOMEA FICILI, Bataille, Bollag, Brana, Britten, Byron, Candido, Catalanotti, Chakraborty, Chang, Chapman, Chen, Chmielowski, CLAUDIO GUARNERI, Comin-Anduix, Corcoran, Curti, Davar, Davies, DEMETRIOS A. SPANDIDOS, Di Giacomo, Donia, Eisen, Eisen, Emery, Falchook, Falchook, Fellner, Feng, Flaherty, Flaherty, FRANCA MARIA PEZZINO, Garnett, Gilmartin, Gray-Schopfer, Greger, Hafsi, Hauschild, Hodi, Hodis, Hwu, Ikenoue, Infante, Isakoff, JAMES A. McCUBREY, Jang, Janku, Jessen, Johnson, Joseph, Karasarides, Kim, Kirkwood, Klinac, Levings, Libra, Ligresti, Lipkin, Lipson, Liu, Lo, Long, Mansh, Markman, MASSIMO LIBRA, McCubrey, McCubrey, McCubrey, Meier, Melero, Melero, Mendoza, Mijatovic, Oberholzer, Ogita, Pecuchet, Robert, Robert, Russo, SALVATORE TRAVALI, SAVERIO CANDIDO, Shahabi, Shao, Sondak, Sosman, Stahl, Strumberg, Strumberg, Su, Thomas, Thomas, Thompson, Tjin, Topalian, Trefzer, Trunzer, Tsai, Venesio, Villanueva, Viola, Vredeveld, Wargo, Weber, Wilhelm, Wilhelm, Wilmott, Wolchok, Yamaguchi, Zhao, Zhao   +119 more
core   +2 more sources

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

Nature Medicine, 2022
The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs.
KarlaA Lee, A. M. Thomas, L. Bolte, J. Björk, L. K. de Ruijter, F. Armanini, F. Asnicar, A. Blanco-Míguez, R. Board, N. Calbet-Llopart, L. Derosa, N. Dhomen, K. Brooks, M. Harland, M. Harries, E. Leeming, P. Lorigan, P. Manghi, R. Marais, J. Newton-Bishop, L. Nezi, Federica Pinto, M. Potrony, S. Puig, P. Serra-Bellver, H. Shaw, S. Tamburini, S. Valpione, Amrita Vijay, L. Waldron, L. Zitvogel, Moreno Zolfo, E. de Vries, Paul Nathan, R. Fehrmann, V. Bataille, G. Hospers, T. Spector, R. Weersma, N. Segata   +39 more
semanticscholar   +1 more source

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma

Frontiers in Medicine, 2019
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced ...
Taku Fujimura, Yota Sato, Kayo Tanita, Chunbing Lyu, Yumi Kambayashi, Ryo Amagai, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Hiroo Hata, Takeru Funakoshi, Yumi Nonomura, Ryota Tanaka, Hisako Okuhira, Naoko Wada, Akira Hashimoto, Setsuya Aiba   +19 more
doaj   +1 more source

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma

Frontiers in Oncology, 2021
Combination immunotherapy can overcome the limited objective response rates of PD-1 blockade. Interferon alpha (IFN-α) has been proven to be effective in modulating immune responses and may enhance the clinical responses to PD-1 blockade.
Dong-Dong Jia, Yanling Niu, Honglin Zhu, Sizhen Wang, Tonghui Ma, Tao Li   +5 more
doaj   +1 more source

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports [PDF]

, 2014
Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen4 (CTLA-4), an inhibitory molecule typically expressed on T cells. Blockade of CTLA-4 induces an overall activation of T cells, including an immune-mediated anti-tumour ...
Brochez, Lieve, Cocquyt, Veronique, KRUSE, VIBEKE, Marlier, Joke, Van Belle, Simon   +4 more
core   +2 more sources

miR-335 Acts as a Tumor Suppressor and Enhances Ionizing Radiation-Induced Tumor Regression by Targeting ROCK1

Frontiers in Oncology, 2020
Recent development of integrative therapy against melanoma combines surgery, radiotherapy, targeted therapy, and immunotherapy; however, the clinical outcomes of advanced stage and recurrent melanoma are poor.
Yanfeng Cheng, Peng Shen
doaj   +1 more source

A practical nomogram and risk stratification system predicting the cancer-specific survival for patients aged >50 with advanced melanoma

Frontiers in Oncology, 2023
ObjectiveTo investigate risk factors for advanced melanoma over 50 years of age and to develop and validate a new line chart and classification system.MethodsThe SEER database was screened for patients diagnosed with advanced melanoma from 2010 to 2019 ...
Qiufen Xi, Xiaoou Lu, Jiali Zhang, Da Wang, Yu Sun, Hongquan Chen   +5 more
doaj   +1 more source

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. [PDF]

, 2016
Several immunomodulatory checkpoint inhibitors have been approved for the treatment of patients with advanced melanoma, including ipilimumab, nivolumab and pembrolizumab.
Ascierto, P.A., Blank, C.U., Hoeller, C., Michielin, O., Szabo, Z.   +4 more
core   +1 more source

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma

Current Oncology Reports, 2023
Purpose of Review Dual immune checkpoint inhibition with ipilimumab plus nivolumab is currently the most effective, but also by far the most toxic treatment for advanced melanoma.
Lea-Jessica Albrecht, E. Livingstone, L. Zimmer, D. Schadendorf   +3 more
semanticscholar   +1 more source